NHS launches world-first GP blood test trial to catch 13 abdominal cancers earlier
More than 20,000 patients aged 45 and over will be offered a single-sample blood test at GP practices across England — the first trial of its kind to test whether family doctors can use multi-cancer detection to speed up diagnosis.
When a patient walks into a GP surgery in England complaining of persistent bloating or abdominal discomfort, the odds are heavily against a cancer diagnosis following — currently just 2 to 6 per cent of urgent cancer referrals result in one. A new government-funded trial launching across at least 200 GP practices aims to change that, by putting a single-sample blood test capable of screening for 13 different cancers into the hands of family doctors for the first time.
The trial, called STRIDE-RCT, will recruit more than 20,000 NHS patients aged 45 and over who visit a participating practice with abdominal symptoms. According to the government, the tests will be evaluated for their ability to identify early indicators of bowel, small bowel, stomach, oesophageal, pancreatic, liver, bile duct and gallbladder, ovarian, endometrial, kidney, bladder and prostate cancer at a point before more serious symptoms emerge.
The scale of the problem the trial is trying to solve is stark. Each year in England, roughly 71,000 people receive diagnoses of pancreatic, stomach, liver, ovarian or bowel cancer, and nearly 35,000 of those patients die from those diseases. Detection at a late stage is a particular problem with abdominal cancers: while approximately nine in ten bowel cancer patients diagnosed at stage 1 live for at least five years, that figure falls to roughly one in ten for those diagnosed at stage 4.
Detecting abdomen cancer early is notoriously difficult because the symptoms can easily be mistaken for other less serious conditions, but the NHS is determined to find a solution. The trial will help determine whether blood tests can help GPs get the right patients to the right tests sooner, supporting earlier diagnosis when treatment is most likely to be successful.— Professor Peter Johnson, NHS National Clinical Director for Cancer and Chair of the Office for Life Sciences Cancer Goal
Most of the tests, developed by the University of Birmingham, require patients to give one or two tubes of blood at their GP practice alongside routine blood tests. The technology uses a combination of artificial intelligence and protein measurement to look for signs of several cancers in a single sample and indicate where in the body they may originate, according to the government. On its own, a positive result does not confirm a cancer diagnosis; rather, it is meant to inform the conversation between GP and patient about whether an urgent referral is warranted.
By giving GPs an additional tool to triage who needs further investigation, the government says the technology could reduce the volume of urgent referrals that do not lead to a diagnosis, freeing up specialist appointments for those with a genuine urgent need.
The earlier cancers are diagnosed, the more chance they can be successfully treated, and lives can be saved. This world-first trial will establish whether simple blood tests can help GPs identify much sooner the patients who need urgent support. Innovations like these are a key part of our National Cancer Plan, which will provide faster diagnosis, more effective treatment, and better care for every patient, while also investing in the trials and technology that offer hope of curing cancer for good.— Yvette Cooper, Secretary of State for Health and Social Care
Funding of up to £8.49 million has been provided by the Office for Life Sciences through the government's National Institute for Health and Care Research (NIHR). It is designed to cover a broad range of communities including inner-city, rural, seaside and deprived areas. The government said the trial will assess how well the tests work alongside GPs' clinical judgement before any decision is made on rolling them out nationwide.
The STRIDE-RCT trial is distinct from earlier NHS liquid biopsy programmes focused on specific cancers such as lung and breast cancer, according to reporting from multiple outlets. The government framed the announcement as part of its broader National Cancer Plan and Life Sciences Sector Plan, citing ambitions for the UK to become Europe's leading life sciences economy by 2030.
Cancer affects all of us at some point in our lives, and millions of people up and down the country will know how it feels to face that awful uncertainty while they wait for a diagnosis. Finding cases early is key – giving patients a clear path to treatment and helping save lives.— Jonathan Reynolds, Secretary of State for Business, Innovation, Science and Trade
According to The Times, the trial spans 200 practices and will examine whether the tests can improve early diagnosis and boost survival rates. If the evidence supports wider use, the tests could eventually become a standard part of the GP consultation for patients presenting with abdominal symptoms — a shift that would represent a significant change in how some of England's most lethal cancers are first identified.
Why it matters — Abdominal cancers are among England's deadliest precisely because they are caught late — this trial could determine whether a simple GP blood test becomes a routine tool that shifts diagnosis from stage 4 to stage 1, where survival rates are dramatically higher.
⚠ Not yet confirmed
- Partner companies alongside the University of Birmingham contributed to developing the blood tests used in the trial.
- verbatim Peter Johnson quote (adjusted wording and removed quotation marks for accuracy)
Reported by gov.uk, reuters.com, thetimes.com
- Yvette CooperBritish politician (born 1969)